TORONTO, Ontario, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that Conavi Medical Inc. (“Conavi”) has received the requisite shareholder approval required to proceed with the proposed combination of Titan and Conavi (the “Amalgamation”) in an all-stock transaction (the “Transaction”).

多伦多，安大略省，2024年9月26日（环球通讯社）--Titan Medical Inc.（“Titan”）（TSX:TMD；OTC:TMDIF）很高兴地宣布，Conavi Medical Inc.（“Conavi”）已获得必要的股东批准，以便在全股票交易（“交易”）中继续进行Titan和Conavi的拟议合并（“合并”）。

This Transaction will constitute a reverse takeover of Titan.The Conavi shareholder approval of the Amalgamation was obtained at a special meeting of its shareholders (the “Conavi Special Meeting”) held today, September 26, 2024. 100% of the shares voted at the Conavi Special Meeting, were voted in favor of the proposal to approve the Amalgamation.

该交易将构成对Titan的反向收购。在今天（2024年9月26日）举行的股东特别会议（“Conavi特别会议”）上，获得了Conavi股东对合并的批准。在Conavi特别会议上，100%的股份被投票赞成批准合并的提议。

'We would like to thank our shareholders for their continued trust and support,” commented Tom Looby, Chief Executive Officer of Conavi. “This vote underscores their confidence in the Amalgamation with Titan and the exciting commercial path we have set for the future of our proprietary Novasight Hybrid™ System, the first technology platform to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries.”“The completion of the Conavi shareholder approval is another important step in the process to close the Transaction” said Paul Cataford, Titan’s Interim CEO and Board Chairman.

Conavi首席执行官汤姆·鲁比（TomLooby）评论道：“我们要感谢股东的持续信任和支持。”。“此次投票突显了他们对与Titan合并的信心，以及我们为专有Novasight Hybrid™系统的未来设定的激动人心的商业道路，该系统是第一个结合IVUS和OCT的技术平台，可实现冠状动脉的同时和共同注册成像。”“完成Conavi股东批准是完成交易过程中的另一个重要步骤”，Titan临时首席执行官兼董事会主席保罗·卡塔福德（PaulCataford）表示。

“Such a high approval for all shareholder resolutions is demonstrative of a high level of commitment and engagement for the shareholder base of a combined company”. The completion of the Transaction remains subject to, among other things, satisfaction of the requirements in the TSX Venture Exchange’s (“TSXV”) conditional approval letter and the closing conditions described in the Amalgamation Agreement, as amended, including completion of Conavi’s concurrent private pla.

“对所有股东决议的高度认可表明了对合并公司股东基础的高度承诺和参与”。除其他事项外，交易的完成仍需满足多伦多证券交易所（“TSXV”）有条件批准函中的要求以及合并协议（经修订）中描述的交割条件，包括完成Conavi的并行私人pla。